title: Mining biomarkers in human sera using proteomic tools.
abstract: One of the major difficulties in mining low abundance biomarkers from serum or plasma is due to the fact that a small number of proteins such as albumin, alpha2-macroglobulin, transferrin, and immunoglobulins, may represent as much as 80% of the total serum protein. The large quantity of these proteins makes it difficult to identify low abundance proteins in serum using traditional 2-dimensional electrophoresis. We recently used a combination of multidimensional liquid chromatography and gel electrophoresis coupled to matrix-assisted laser desorption/ionization-quadrupole-time of flight and Ion Trap liquid chromatography-tandem mass spectrometry to identify protein markers in sera of Alzheimer's disease (AD), insulin resistance/type-2 diabetes (IR/D2), and congestive heart failure (CHF) patients. We identified 8 proteins that exhibit higher levels in control sera and 36 proteins that exhibit higher levels in disease sera. For example, haptoglobin and hemoglobin are elevated in sera of AD, IR/D2, and CHF patients. The levels of several other proteins including fibrinogen and its fragments, alpha 2-macroglobulin, transthyretin, pro-platelet basic protein, protease inhibitors clade A and C, as well as proteins involved in the classical complement pathway such as complement C3, C4, and C1 inhibitor, were found to differ between IR/D2 and control sera. The sera levels of proteins, such as the 10 kDa subunit of vitronectin, alpha 1-acid glycoprotein, apolipoprotein B100, fragment of factor H, and histidine-rich glycoprotein were observed to be different between AD and controls. The differences observed in these biomarker candidates were confirmed by Western blot and the enzyme-linked immunosorbent assay. The biological meaning of the proteomic changes in the disease states and the potential use of these changes as diagnostic tools or for therapeutic intervention will be discussed.
authors.affiliation: Syn-X Pharma, Toronto, Ontario, Canada. rzhang@synxpharma.com
authors.forename: Rulin
authors.initials: R
authors.lastname: Zhang
authors.forename: Lisa
authors.initials: L
authors.lastname: Barker
authors.forename: Deborah
authors.initials: D
authors.lastname: Pinchev
authors.forename: John
authors.initials: J
authors.lastname: Marshall
authors.forename: Michèle
authors.initials: M
authors.lastname: Rasamoelisolo
authors.forename: Chris
authors.initials: C
authors.lastname: Smith
authors.forename: Peter
authors.initials: P
authors.lastname: Kupchak
authors.forename: Inga
authors.initials: I
authors.lastname: Kireeva
authors.forename: Leslee
authors.initials: L
authors.lastname: Ingratta
authors.forename: George
authors.initials: G
authors.lastname: Jackowski
mesh_terms: D015415:Biomarkers / Q000097:blood*; D002853:Chromatography, Liquid; D015180:Electrophoresis, Gel, Two-Dimensional; D006801:Humans; D013058:Mass Spectrometry; D020543:Proteome / Q000032:analysis / Q000737:chemistry*; D040901:Proteomics; D009626:Terminology as Topic
chemical_list: D015415:Biomarkers; D020543:Proteome